ESMO VIRTUAL PRECEPTORSHIP PROGRAMME
GASTRIC CANCER
Multidisciplinary management, standards of care, therapeutic targets and future perspectives
23-24 October 2020

CO-CHAIRS: Andrés Cervantes, Spain
Fiorian Lordick, Germany

SPEAKERS: William Allum, United Kingdom
Maria Alsina, Spain
Fatima Carneiro, Portugal
Valentina Gambardella, Spain
Karin Haustermans, Belgium
Elizabeth Smyth, United Kingdom

LEARNING OBJECTIVES

- To learn about the fundamentals of epidemiology, aetiology, pathogenesis, molecular events and ethnic patterns as contributing factors to heterogeneity in gastric cancer
- To understand the essentials in the diagnosis and multidisciplinary treatment of gastric cancer
- To learn about advances in the treatment and novel targets in gastric cancer

All timings are to be considered CEST (Central European Summer Time)

Friday, 23 October 2020

| 15:00-15:10  | Opening and welcome |
| 10’          | Welcome from ESMO and introduction | Andrés Cervantes, ES |

| 15:10-17:10  | SESSION 1          |
| 120’         | Localized gastroesophageal adenocarcinomas | Moderator: Andrés Cervantes, ES |

| 25’          | Pathology assessment of gastric and junctional adenocarcinomas | Fatima Carneiro, PT |
| 25’          | The role of surgery in localized gastric and junctional cancers | William Allum, UK |
| 25’          | Developments in radiotherapy for localized gastric and junctional cancers | Karin Haustermans, BE |

| 16:25-16:35  | Coffee break      |
| 25’          | Neoadjuvant and adjuvant therapy for localized gastric and junctional cancers | Elizabeth Smyth, UK |
| 10’          | Q&A                | Faculty |
### SESSION 2

**Cases discussion of localized disease**

**Moderator:** Andrés Cervantes, ES

- **5x15’**
  - 5 x Participants clinical case discussion
  - Faculty

---

### SESSION 3

**Treatment for advanced gastroesophageal adenocarcinomas**

**Moderator:** Florian Lordick, DE

- **20’**
  - First line treatment for HER2 non amplified advanced gastroesophageal adenocarcinomas
  - Florian Lordick, DE

- **20’**
  - Treatment for HER2 amplified and advanced gastroesophageal adenocarcinomas
  - Andrés Cervantes, ES

- **20’**
  - Second line treatment and beyond for advanced gastroesophageal adenocarcinomas (including chemo and targeted agents)
  - Maria Alsina, ES

---

### Coffee Break

- **16:00-16:10**
  - **20’**
    - The use of Immunotherapy after first line in advanced gastroesophageal adenocarcinomas
    - Elizabeth Smyth, UK
  - **20’**
    - Looking for precision medicine in advanced gastroesophageal adenocarcinomas
    - Valentina Gambardella, ES
  - **10’**
    - Q&A
    - Faculty

---

### SESSION 4

**Cases discussion of advanced disease**

**Moderator:** Florian Lordick, DE

- **5x15’**
  - 5 x Participants clinical case discussion
  - Faculty

---

**Note:** Each 15-minute slot for clinical case discussion includes 7’ case presentation and 8’ Q&A / panel discussion